Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes



  Analyses presented at EASD support Trajenta® (linagliptin) as effective and
  well-tolerated for patients with type 2 diabetes with different background
  therapies

Business Wire

BERLIN -- October 02, 2012

EX US & UK.
Medical Media Only.

Boehringer Ingelheim and Eli Lilly and Company today announced results from a
large Phase III study and three pooled analyses of Phase III data presented at
the 48th European Association for the Study of Diabetes (EASD) Annual Meeting,
which support Trajenta^® (linagliptin) as effective and well-tolerated for
patients with type 2 diabetes (T2D), including the elderly and those with
diabetic nephropathy.^1,2 ,3,4 Linagliptin is a once-daily tablet that is used
as monotherapy in patients inadequately controlled by diet and exercise alone
and for whom metformin is inappropriate due to intolerance, or contraindicated
due to renal impairment. Linagliptin is also approved in combination with
metformin and metformin + sulphonylurea.^5

“Unfortunately type 2 diabetes can be a complex and challenging condition to
treat,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine,
Boehringer Ingelheim. “Many patients are elderly, or are affected by
co-morbidities. As our clinical evidence base grows, so does our confidence
that linagliptin offers an effective and well-tolerated treatment option for
patients with type 2 diabetes in need of effective blood glucose control.”

Boehringer Ingelheim and Eli Lilly presented the results of a Phase III study,
which evaluated the long-term safety and efficacy of the addition of
linagliptin vs. placebo in 1261 patients inadequately controlled on basal
insulin therapy*. The overall safety and tolerability for linagliptin was
comparable to placebo. The incidence of hypoglycaemia was also comparable in
both groups (linagliptin 31.4%, placebo 32.9%), despite better glycaemic
control with linagliptin (-0.53% placebo-adjusted change in HbA1c from
baseline at week 52 (P<0.0001). HbA1c is measured in people with diabetes to
provide an index of blood glucose control for the previous two to three
months. Body weight was stable over the treatment period in both groups.^1

Linagliptin as add-on to basal insulin therapy* has also shown safety and
efficacy in elderly patients (≥ 70 years) in a separate pre-specified pooled
analysis of two Phase III studies, evaluating linagliptin vs. placebo as
add-on therapy to basal insulin and as T2D management in elderly patients,
over 24 weeks. Elderly patients with T2D are commonly characterised by longer
disease duration and diminished beta-cell capacity, which often requires
combination therapy with basal insulin. In this vulnerable elderly population,
linagliptin in combination with basal insulin was well-tolerated with the
overall incidence of adverse events (AE) not higher than placebo. Linagliptin
achieved improvements in glycaemic control of -0.77% (placebo-adjusted change
in HbA1c from baseline (P<0.0001)), without excessive risk of hypoglycaemia
(hypoglycaemia occurred in 28.6% on linagliptin and 37.2% on placebo).^4

A third analysis of seven Phase III trials assessed a variety of safety and
efficacy parameters associated with linagliptin use in elderly T2D patients (≥
65 years) as monotherapy or add-on to various glucose-lowering therapies.
Results from this analysis showed that linagliptin is well-tolerated and might
be a treatment option for elderly patients (≥ 65 years) without the need for
dose adjustment.*

Linagliptin showed a reduction in glucose levels as measured by a −0.62%
(P<0.0001, placebo-adjusted) change in HbA1c from baseline to week 24.
Patients treated with linagliptin also experienced a significantly greater
reduction in fasting plasma glucose (FPG) (placebo-adjusted mean change of
−14.8 mg/dL, P<0.0001; −0.82 mmol/L) and the number of AEs was not higher than
those on placebo (71.3% vs. 73.3%). Drug-related AEs were also not higher with
linagliptin compared to placebo (18.1% vs. 19.8%).^3

“This is very encouraging data in this often challenging-to-treat patient
population,” said Professor Anthony Barnett, Emeritus Professor of Medicine,
University of Birmingham, UK. “Many elderly patients have additional safety
and tolerability concerns, such as co-morbidities, compromised renal function
and heightened risk of hypoglycaemia. Linagliptin appears to be an effective
and well-tolerated treatment option for type 2 diabetes in the elderly without
the need for dose adjustment or extra monitoring even if kidney function
declines. In a situation where treatment choices are more and more limited,
linagliptin is a welcome addition to our therapeutic armamentarium.”

In a separate analysis, linagliptin showed efficacy in another vulnerable T2D
patient population – those with diabetic nephropathy. Many patients with T2D
have diabetic nephropathy shortly after diagnosis, and may go on to develop
end stage kidney disease. Currently, there are only very limited oral
treatment options available for T2D patients with renal disease. An analysis
of seven randomised trials was performed and data after 24 weeks of treatment
were generated to allow pooling and two sets were defined: Diabetic
nephropathy in earlier stages of T2D: patients with persistent albuminuria
(30<=UACR [Urine Albumin-to-creatine Ratio] <=3000 mg/g) and stable treatment
with an ACEi [Angiotensin Converting Enzyme inhibitor] or ARB [Angiotensin II
Receptor Blocker] (Set 1); Diabetic nephropathy in elderly patients (≥65
years), who fulfilled UACR criteria (Set 2). Patients from Set 1 were treated
with or without oral glucose lowering background therapies and patients from
Set 2 had various glucose lowering background therapies, including insulin
therapy.

Patients in Set 1 experienced placebo-corrected changes in HbA1c and fasting
plasma glucose of -0.71% and -1.4 mmol respectively (both P<0.0001).
Linagliptin also significantly lowered UACR by 33% (P<0.05). In Set 2
Linagliptin significantly lowered adjusted UACR by 30% (P<0.05). The reduction
of albuminuria was beyond what may be expected by the glucose-lowering effects
of linagliptin in both Sets.^2

Linagliptin (5 mg, once daily) is marketed in Europe as Trajenta^®
(linagliptin) and in the U.S. as Tradjenta^® (linagliptin), as a once-daily
tablet that is used along with diet and exercise to improve glycaemic control
in adults with T2D. Linagliptin should not be used in patients with type 1
diabetes or for the treatment of diabetic ketoacidosis (increased ketones in
the blood or urine). In Europe, Linagliptin is not approved for use in
combination with insulin. With linagliptin, no dose adjustment is required
regardless of declining renal function or hepatic impairment^†.^5

                                    ~ends~

Please click on the link below for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2012/02_october_2012_linagliptin.html

*Currently linagliptin is approved for use as add-on therapy to insulin in the
US. It is not currently approved for use in this indication in the EU.

^†Please also see EU SmPC.

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50421591&lang=en

Contact:

Boehringer Ingelheim GmbH
Arnd Prilipp
Launch and Established Products CVM
Email: arnd.prilipp@boehringer-ingelheim.com
Phone: +49 (6132) 77-2091
or
Lilly Diabetes
Tammy Hull
Communications Manager
Email: hullta@lilly.com
Phone: (317) 651-9116
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement